Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study

Klil-Drori, Adi J.; Yin, Hui; Azoulay, Laurent; Harnois, Michaël; Gratton, Michel-Olivier; Busque, Lambert; Assouline, Sarit

doi:10.3324/haematol.2018.211235

Cited by 6 publications

(6 citation statements)

References 15 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While majority of studies have shown that generic and innovator imatinib are equally efficacious 15 , a few have suggested loss of responses when switched from innovator to generic version of imatinib 8 . Besides, certain studies have also suggested that medication persistence may be lower with generic imatinib, mainly driven by excessive adverse events as compared to innovator 19 . Persistence on a given TKI for more than three years and attainment of DMR - both are pre-requisites for TFR trial; therefore, a TFR study on generic imatinib potentially addressees both tolerability and efficacy controversies that surround generic imatinib use.…”

Section: Resultsmentioning

confidence: 99%

Feasibility of treatment-free remission with generic imatinib

Malhotra¹,

Goni²,

Jain³

et al. 2023

Indian Journal of Medical Research

View full text Add to dashboard Cite

Background & objectives: Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukaemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment-free remission (TFR) with generic imatinib. This study attempted to determine the feasibility and efficacy of TFR in patients on generic Imatinib. Methods: In this single-centre prospective Generic Imatinib-Free Trial-in-CML-CP study, twenty six patients on generic imatinib for ≥3 yr and in sustained deep molecular response (BCR ABL IS ≤0.01% for more than two years) were included. After treatment discontinuation, patients were monitored with complete blood count and BCR ABL IS by real-time quantitative PCR monthly for one year and three monthly thereafter. Generic imatinib was restarted at single documented loss of major molecular response (BCR ABL IS >0.1%). Results: At a median follow up of 33 months (interquartile range 18.7-35), 42.3 per cent patients (n=11) continued to be in TFR. Estimated TFR at one year was 44 per cent. All patients restarted on generic imatinib regained major molecular response. On multivariate analysis, attainment of molecularly undetectable leukaemia (>MR 5 ) prior to TFR was predictive of TFR [ P =0.022, HR 0.284 (0.096-0.837)]. Interpretation & conclusions: The study adds to the growing literature that generic imatinib is effective and can be safely discontinued in CML-CP patients who are in deep molecular remission.

show abstract

Section: Resultsmentioning

confidence: 99%

Feasibility of treatment-free remission with generic imatinib

Malhotra¹,

Goni²,

Jain³

et al. 2023

Indian Journal of Medical Research

View full text Add to dashboard Cite

show abstract

“…In contrast, a Canadian prospective matched cohort study analyzed the rate of persistence with generic and branded imatinib: a 3-year rate of persistence with the generic was significantly inferior to that of the branded imatinib (72.8% vs. 88.2%; P=0.03), with a probability of switching, which was two-fold higher for generic than for branded imatinib. Among patients who opted for the generic drug, 25 (69.5%) had to switch for intolerance and 12 (33.3%) for resistance [23]. With increasing data demonstrating comparable efficacy of generic imatinib, it is reasonable to expect that similar data may be obtained in case of discontinuation of the generic treatment.…”

Section: Discussionmentioning

confidence: 99%

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

et al. 2020

View full text Add to dashboard Cite

“…Uyanik MS et al [12], Klil-Drori AJ et al [13] ont montré une aggravation des effets secondaires après le passage de la molécule d'origine au générique. Chez les patients initialement mis sous générique, Abdalla Awidi et al ont montré que 89 % ont eu des effets secondaires dont 13,5 % sont de grade 3 et 4 [14].…”

Section: Page14unclassified

Generic Imatinib Mesylate as first line treatment of chronic myeloid leukemia

Benzineb,

Melsi,

Bekadja

et al. 2023

Batna J Med Sci

View full text Add to dashboard Cite

Background. In order to reduce the cost of treating diseases, governments tend to use generic drugs, as in the case of chronic myeloid leukemia (CML). The aim of this study is to evaluate the therapeutic efficacy of an Imatinib Mesylate (IM) generic drug as first line treatment of CML. Patients and methods. A retrospective (01-01-2017 to 31-12-2018) multicenter study, related to patients with CML in the chronic phase and treated with the IM generic as a first line therapy. Results. We collected data of 392 patients. Median age was 48 (16-85) years. In 43% of cases, treatment was stopped following resistance or intolerance, of which 2.8% of cases progressed to an advanced phase. 2.6% of patients lost their molecular and hematological response. Overall survival (OS) was 76.4%. OS was poor in the high Sokal-score group (69%) compared to the low (73%) and intermediate (81.4%) risk groups (p: 0.01). Conclusion. The choice of the a generic IM as first-line treatment of CML makes it possible to obtain a satisfactory response rate and a good safety profile.

show abstract

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study

Cited by 6 publications

References 15 publications

Feasibility of treatment-free remission with generic imatinib

Feasibility of treatment-free remission with generic imatinib

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

Generic Imatinib Mesylate as first line treatment of chronic myeloid leukemia

Contact Info

Product

Resources

About